BLISS BIOPHARMACEUTICAL TO PRESENT DATA ON BB-1701 COHORT EXPANSION OF PHASE I STUDY AT 2023 ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM

2023-12-06

BLISS BIOPHARMACEUTICAL TO PRESENT DATA ON BB-1701 COHORT EXPANSION OF PHASE I STUDY AT 2023 ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM

百力司康将携 BB-1701 亮相美国圣地亚哥第 14 届 World ADC 大会

2023-10-17

百力司康CEO魏紫萍博士受邀将于2023年10月17日在美国圣地亚哥举办的2023年第14届World ADC大会就BB-1701项目做口头演讲。

BlissBio Completes Series B++ Financing, Invested by Eisai

2023-06-07

HANGZHOU, June 06, 2023 --- Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (“BlissBio”) announced the completion of Series B++ financing invested by Eisai Co., Ltd (“Eisai”).

BLISSBIO TO PRESENT DATA ON BB-1701 PHASE 1 STUDY AT 2023 ASCO ANNUAL MEETING

2023-06-03

Bliss Biopharmaceutical (Hangzhou) Co., Ltd, (“BlissBio”) a clinical-stage biopharmaceutical company developing differentiated antibody-drug conjugate (ADC) therapeutics, announced today BB-1701 Phase 1 study data will be presented at the American Society of Clinical Oncology (2023 ASCO Annual Meeting), to be held from June 2 to 6, 2023.

BLISS BIOPHARMACEUTICAL ENTERS INTO A CLINICAL TRIAL COLLABORATION AGREEMENT WITH AN OPTION OF STRATEGIC COLLABORATION WITH EISAI FOR BB-1701

2023-05-08

On May 8, 2023, BlissBio, a clinical-stage biopharmaceutical company developing differentiated ADC therapeutics, announced a clinical trial collaboration agreement with option for strategic collaboration with Eisai for BB-1701.

【荣耀时刻】百力司康进入中国创新生物医药榜100强

2023-05-07

2023年第七届未来医疗100强大会以“无问西东”为主题，于5月5日正式启幕，并于5月6日晚的百强颁奖晚宴上发布了2023年未来医疗100强榜单。